Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

Abstract

The decreasing rank order for pooled efficacy was infliximab, etanercept, efalizumab and alefacept when compared with placebo. Pooling safety data revealed a previously unreported increased risk of AEs for alefacept, efalizumab and infliximab.

Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials

“…The same finding was not seen in patients treated with ustekinumab 90mg probably because at this dosage adverse events are more common. For other safety outcomes, there was no statistically significant difference between biological agents and placebo, as confirmed by other studies 7,8,12 . Nevertheless, these results must be considered cautiously by clinicians and managers.…”

“…Of these, only Reich et al 10 included the biologic ustekinumab in the metaanalysis. Moreover, few studies address safety outcomes 7,8,12 . Drugs included in this study were: adalimumab, alefacept, anakinra, briakinumab, certolizumab, efalizumab, etanercept, infliximab, golimumab, rituximab, siplizumab, onercept and ustekinumab.…”

“…Through a database search, we found meta-analyses that evaluated only one biological agent against placebo and others including more than one agent 4,5,6,7,8,9,10,11,12,13 . Of these, only Reich et al 10 included the biologic ustekinumab in the metaanalysis.…”

Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis

“…The significant overexpression of type 1 IFN-inducible genes in the blood of patients with DM or PM is likely to provide an effective pharmacodynamic marker for assessing anti-type 1 IFN monoclonal antibody therapy in these patients, as in the case of SLE. 27 High correlation of significant expression changes in type 1 IFN-inducible genes in peripheral blood with major changes in disease activity additionally suggests that their measurement has potential utility to monitor disease activity of patients with DM or PM during treatment courses. An important limitation of this study is its performance in the context of routine clinical care.…”

Biologicals in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method

“…Infliximab was also more effective than etanercept, which was confirmed in two meta-analyses [58,59]. One of these analyses also showed superiority of adalimumab to etanercept [59].…”